Methylenedioxyallylamphetamine
(Redirected from MDAL)
 | This article relies largely or entirely on a single source. (October 2017) |
| File:MDAL.svg | |
| Clinical data | |
|---|---|
| Other names | MDAL; 3,4-Methylenedioxy-N-allylamphetamine |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C13H17NO2 |
| Molar mass | 219.284 g·mol−1 |
| 3D model (JSmol) | |
| |
| ☒check (what is this?) (verify) | |
Methylenedioxyallylamphetamine (MDAL or 3,4-methylenedioxy-N-allylamphetamine) is a lesser-known drug.[1] It is also the N-allyl derivative of 3,4-methylenedioxyamphetamine (MDA).[1] MDAL was first synthesized by Alexander Shulgin.[1] In his book PiHKAL, the minimum dose is listed as 180 mg, and the duration unknown.[1] MDAL produces few to no effects on its own, but may enhance the effects of psychedelic drugs like LSD.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.[1]
Society and culture
[edit | edit source]Legal status
[edit | edit source]United Kingdom
[edit | edit source]This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]
See also
[edit | edit source]- Substituted methylenedioxyphenethylamine
- Benzofuranylpropylaminopentane
- Phenylpropylaminopentane
- MDPR